A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma - PubMed (original) (raw)

Clinical Trial

. 2017 Jun 1;123(11):1979-1988.

doi: 10.1002/cncr.30571. Epub 2017 Feb 13.

Hui Zheng 3, Matthew B Yurgelun 2 4, Thomas A Abrams 2 4, Jill N Allen 1 2, James M Cleary 2 4, Michelle Knowles 1, Eileen Regan 4, Amanda Reardon 1, Anna Khachatryan 5, Rakesh K Jain 2 5, Valentina Nardi 2 6, Darrell R Borger 2 6, Dan G Duda 2 5, Andrew X Zhu 1 2

Affiliations

Clinical Trial

A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma

Lipika Goyal et al. Cancer. 2017.

Abstract

Background: Advanced cholangiocarcinoma carries a poor prognosis, and no standard treatment exists beyond first-line gemcitabine/platinum-based chemotherapy. A single-arm, phase 2 and biomarker study of cabozantinib, a multikinase inhibitor with potent activity against vascular endothelial growth factor receptor 2 (VEGFR2) and MET, was performed for patients with advanced refractory cholangiocarcinoma.

Methods: Previously treated patients with unresectable or metastatic cholangiocarcinoma received cabozantinib (60 mg orally and daily on a continuous schedule). The primary endpoint was progression-free survival (PFS). Tumor MET expression and plasma biomarkers were evaluated.

Results: The study enrolled 19 patients with cholangiocarcinoma (female, 68%; median age, 67 years; intrahepatic vs extrahepatic, 84% vs 16%). The median PFS was 1.8 months (95% confidence interval, 1.6-5.4 months), and the median overall survival (OS) was 5.2 months (95% confidence interval, 2.7-10.5 months). Grade 3/4 adverse events occurred in 89% of the patients and included neutropenia (5%), hyperbilirubinemia (5%), epistaxis (5%), bowel perforation (5%), enterocutaneous fistulas (5%), and hypertension (11%). One patient with 3 + MET expression in the tumor stayed on treatment for 278 days, but the MET expression did not correlate with the outcomes in the overall study population. Plasma vascular endothelial growth factor, placental growth factor, and stromal cell-derived factor 1α increased and soluble VEGFR2 and angiopoietin 2 decreased after treatment (all P values < .01). Plasma tissue inhibitor of matrix metalloproteinase 1 was inversely correlated with PFS, and soluble MET (sMET) and interleukin 6 were inversely correlated with OS.

Conclusions: In unselected patients with cholangiocarcinoma, cabozantinib demonstrated limited activity and significant toxicity. In the first clinical trial to assess the role of MET inhibition in cholangiocarcinoma, 1 patient with a MET-high tumor had a prolonged benefit from treatment. Baseline plasma soluble MET was associated with OS. Any further development of this drug in cholangiocarcinoma should include a dose reduction and a biomarker-driven approach. Cancer 2017;123:1979-1988. © 2017 American Cancer Society.

Trial registration: ClinicalTrials.gov NCT01954745.

Keywords: cabozantinib; cholangiocarcinoma; phase 2; soluble MET; vascular endothelial growth factor receptor 2 (VEGFR2).

© 2017 American Cancer Society.

PubMed Disclaimer

Conflict of interest statement

All other authors declare no conflicts of interest.

Figures

Figure 1

Figure 1. Total MET immunohistochemistry

Levels of total MET protein were evaluated in patient archived pre-treatment FFPE tumor tissue. Shown are representative photomicrographs captured using a 40X objective across the IHC scores of A) 0 (study ID #3), B) 1+ (study ID #11), C) 2+ (study ID #14) and D) 3+ (study ID #5).

Figure 1

Figure 1. Total MET immunohistochemistry

Levels of total MET protein were evaluated in patient archived pre-treatment FFPE tumor tissue. Shown are representative photomicrographs captured using a 40X objective across the IHC scores of A) 0 (study ID #3), B) 1+ (study ID #11), C) 2+ (study ID #14) and D) 3+ (study ID #5).

Figure 1

Figure 1. Total MET immunohistochemistry

Levels of total MET protein were evaluated in patient archived pre-treatment FFPE tumor tissue. Shown are representative photomicrographs captured using a 40X objective across the IHC scores of A) 0 (study ID #3), B) 1+ (study ID #11), C) 2+ (study ID #14) and D) 3+ (study ID #5).

Figure 1

Figure 1. Total MET immunohistochemistry

Levels of total MET protein were evaluated in patient archived pre-treatment FFPE tumor tissue. Shown are representative photomicrographs captured using a 40X objective across the IHC scores of A) 0 (study ID #3), B) 1+ (study ID #11), C) 2+ (study ID #14) and D) 3+ (study ID #5).

References

    1. Nagino M, Ebata T, Yokoyama Y, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann Surg. 2013;258(1):129–140. - PubMed
    1. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–1281. - PubMed
    1. Walter T, Horgan AM, McNamara M, et al. Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study. Eur J Cancer. 2013;49(2):329–335. - PubMed
    1. Yoshikawa D, Ojima H, Iwasaki M, et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer. 2008;98(2):418–425. - PMC - PubMed
    1. Hida Y, Morita T, Fujita M, et al. Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomas. Anticancer Res. 1999;19(3B):2257–2260. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources